Menu Back toSession-0703-Development-of-Biosimilars-in-China-Interpretation-of-Biosimilar-Guidance-Opportunities-and-Challenges-I

The 7th DIA China Annual Meeting


Session 0703 Development of Biosimilars in China: Interpretation of Biosimilar Guidance, Opportunities and Challenges - I

Session Chair(s)

Joe  Zhang

Joe Zhang

  • Co-founder and CEO
  • BJ Bioscience Inc., China

Global mAb Biosimilar Industry Challenges and Opportunities from Policy to Reality

Speaker(s)

Evangelos  Kotzagiorgis, MPharm, MS

EMA & Biosimilar update Trends and developments in marketing authorisation applications, scientific advice procedures and policies

Evangelos Kotzagiorgis, MPharm, MS

  • Scientific Administrator, Quality of Medicines, Human Medicines Evaluation Div
  • European Medicine Agency, United Kingdom
Joe  Zhou

Global mAb Biosimilar Industry Challenges and Opportunities from Policy to Reality

Joe Zhou

  • CEO
  • Genor BioPharm, Walvax Bio Group, China

Contact us

For exhibition, advertising and hosting inquiry, please contact:
Jean XU: jxu@kellencompany.com, or Sofie Peeters: speeters@kellencompany.com
Tel: +86 10 5923 1096

For general inquiry, please contact DIA China office:
dia@diachina.org
Tel: +86 10 5704 2650